



LAHIVE
&
COCKFIELD
L L P

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)
THOMAS V. SMURZYNSKI
RALPH A. LOREN
GIULIO A. DeCONTI, JR.
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DeANN FORAN SMITH
DEBRA J. MILASINCIC, Ph.D.
DAVID J. RIKKERS
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER
MEGAN E. WILLIAMS, Ph.D.
LISA DIROCCO TYNER
HATHAWAY P. RUSSELL *

MARIA LACCOTRIPE ZACHARAKIS, Ph.D.
MERIDETH C. ARNOLD
DANIELLE L. HERRITT
EUIHOON LEE **
MANEESH GULATI
CYNTHIA M. SOROOS
PETER W. DINI, Ph.D.

SENIOR COUNSEL
JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
WILLIAM A. SCOFIELD, JR.
SIBLEY P. REPPERT
JEANNE M. DiGIORGIO
CYNTHIA L. KANIK, Ph.D.
JOHN D. LANZA

PATENT AGENTS
THEODORE R. WEST
JONATHAN M. SPARKS, Ph.D.
ANDRINA WILLIAMS ZINK

TECHNICAL SPECIALISTS
CATHERINE M. BISHOP
JACOB G. WEINTRAUB
CRISTIN E. HOWLEY, Ph.D.
JILL ANN MELLO, Ph.D.
DEBORAH L. NAGLE, Ph.D.
ANNE JACQUELINE WIZEMAN, Ph.D.
BRIAN C. TRINQUE, Ph.D.
CHRISTOPHER R. COWLES, Ph.D.

* Admitted in TX only
** Admitted in CT only

March 16, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Re: U.S. Patent Application No.: 10/646267
For: *METHODS AND MEANS FOR INHIBITION OF CDK4 ACTIVITY*
Inventors: Ball, Kathryn Lindsay *et al.*
Filed: August 22, 2003
Our Ref. No.: CCI-007USDV

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Information Disclosure Statement;
2. PTO Form 1449; and
3. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.


I hereby certify that this correspondence is deposited with the United States Postal Service as Express Mail, Airbill No. EV 355384263 US, in an envelope addressed to: MS Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450:

March 16, 2004

Date

Cynthia L. Kanik, Ph.D., Reg. No. 37,320

Respectfully submitted,
LAHIVE & COCKFIELD, LLP


Cynthia L. Kanik, Ph.D.
Registration No. 37,320
Attorney for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Ball, Kathryn Lindsay *et al.*

Serial No.: 10/646267

Filed: August 22, 2003

For: *METHODS AND MEANS FOR INHIBITION OF CDK4 ACTIVITY*

Attorney Docket No.: CCI-007USDV

Group Art Unit: 1646

Examiner: Not Yet Assigned

MS Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 355384263 US, in an envelope addressed to: MS Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 16, 2004

By: _____

Cynthia L. Kanik, Ph.D., Registration No. 37,320, Attorney for Applicant

INFORMATION DISCLOSURE STATEMENT

Dear Sir:


Applicants and their Attorney are aware of the following patents, publications or other information, which are cited on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration.

The present application is a Divisional Application of U.S. Serial No. 09/180269, filed July 8, 1999 (Atty. Docket No. CCI-007USRCE). All references listed on the enclosed PTO Form 1449 have been previously cited by or submitted to the Office in the prior application, and, in accordance with 37 CFR §1.98(d), copies of these references are not enclosed herewith, but will be provided upon request.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP



Cynthia L. Kanik, Ph.D.
Registration No. 37,320
Attorney for Applicants
28 State Street
Boston, MA 02109
(617) 227-7400

Date: March 16, 2004

CLK/alf

APPLICANT FACSIMILE OF FORM PTO-1449
 REV-7-80

 U.S. DEPARTMENT OF COMMERCE
 PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

SERIAL NO.

CCI-007USDV

10/646267

APPLICANT

Ball, Kathryn Lindsay *et al.*

FILING DATE

GROUP

August 22, 2003

1646

 LIST OF PUBLICATIONS CITED BY APPLICANT
 (Use several sheets if necessary)


U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	5,807,692	9/98	Kinzler <i>et al.</i>	437	7.21	
	A2	5,672,508	9/97	Gyuris <i>et al.</i>	435	320.1	
	A3	5,596,079	1/97	Smith <i>et al.</i>	530	328	
	A4	5,424,400	6/95	Smith <i>et al.</i>	530	350	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	A5	FR 2,662,698	12/91	France			Abstr.	
	A6	WO 96/35715	11/96	PCT				
	A7	WO 97/42222	11/97	PCT				
	A8	WO 97/03681	2/97	PCT				
	A9	WO 96/14334	5/96	PCT				
	A10	WO 95/06415	3/95	PCT				
	A11	WO 95/13375	5/95	PCT				
	A12	WO 95/31995	11/95	PCT				
	A13	WO 94/09135	4/94	PCT				
	A14	WO 94/02167	2/94	PCT				
	A15	WO 93/12251	6/93	PCT				
	A16	0 002 805	12/78	Europe				

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

		Adams, Peter D. <i>et al.</i> "Identification of a Cyclin-cdk2 Recognition Motif Present in Substrates and p21-Like Cyclin-Dependent Kinase Inhibitors" <i>Molecular and Cellular Biology</i> 16:6623-6633 (Dec 1996).
		Ball, Kathryn L. <i>et al.</i> (1996) "Cell-Cycle Arrest And Inhibition Of Cdk4 Activity By Small Peptides Based On The Carboxy-Terminal Domain Of p21 ^{WAF1} " <i>Current Biology</i> , Vol. 7 pp. 71-80;
		Ball, Kathryn L. <i>et al.</i> (1996) "Human And Plant proliferating-Cell Nuclear Antigen Have A highly Conserved Binding Site For The p53-Inducible Gene product p21 ^{WAF1} " <i>Eur. J. Biochem.</i> Vol. 237 pp. 854-861;
		Chen, Junjie <i>et al.</i> (1996) "p21 ^{Cip1/Waf1} Disrupts The Recruitment Of Human Fen1 By Proliferating-Cell Nuclear Antigen Into The DNA Replication Complex" <i>Proc. Natl. Acad. Sci. USA</i> , Vol 93, pp. 11597-11602;
Examiner		Date Considered
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. CCI-007USDV	SERIAL NO. 10/646267
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Ball, Kathryn Lindsay <i>et al.</i>	
		FILING DATE August 22, 2003	GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

B1	Chen, Junjie <i>et al.</i> (1996) "Cyclin-Binding Motifs Are Essential For The Function of p21 ^{Cip1} " Molecular and Cellular Biology, Vol. 16, No. 9 pp. 4673-4682;
B2	Chen, Junjie <i>et al.</i> (1995) "Separate Domains Of p21 Involved In The Inhibition Of Cdk Kinase And PCNA", Nature, Vol. 374, pp. 386-388;
B3	Chen, I-Tsuen <i>et al.</i> (1996) "Characterization of p21 ^{Cip1/Waf1} Peptide Domains Required For Cyclin E/Cdk2 and PCNA Interaction" Oncogene Vol. 12 pp. 595-607;
B4	Deng, Chuxia <i>et al.</i> (1995) "Mice Lacking p21 ^{Cip1/Waf1} Undergo Normal Development, But Are Defective In G1 Checkpoint Control", Cell, Vol. 82, pp. 675-684;
B5	Eastham, James A. <i>et al.</i> (1995) "In Vivo Gene Therapy with p53 or p21 Adenovirus For Prostate Cancer", Cancer Research, Vol. 55, pp. 5151-5155;
B6	El-Deiry, Wafik S. <i>et al.</i> (1993) "WAF1, A Potential Mediator Of p53 Tumor Suppression" Cell, Vol. 75, pp. 817-825;
B7	Goubin, Francoise <i>et al.</i> (1995) "Identification of Binding Domains on the p21 ^{Cip1} Cyclin-Dependent Kinase Inhibitor" Oncogene, Vol. 10, pp. 2281-2287;
B8	Gu, Yong <i>et al.</i> (1993) "Inhibition Of CDK2 Activity In Vivo By An Associated 20 K Regulatory Subunit" Nature, Vol. 366, pp. 707-710;
B9	Harper, J. Wade <i>et al.</i> (1995) "Inhibition Of Cyclin-Dependent Kinases By p21", Molecular Biology of the Cell, Vol. 6, pp. 387-400;
B10	Harper, J. Wade <i>et al.</i> (1993) "The p21 Cdk-Interacting Protein Cip1 Is A Potent Inhibitor Of G1 Cyclin-Dependent Kinases", Cell, Vol. 75, pp. 805-816;
B11	Hiraoka, Lea R. <i>et al.</i> (1995) "Sequence Of Human FEN-1, A Structure-Specific Endonuclease, And Chromosomal Localization Of The Gene (FEN1) In Mouse And Human" Genomics Vol. 25, pp. 220-225;
B12	Lin, Jiayuh <i>et al.</i> (1996) "Analysis Of Wild-Type and Mutant p21 ^{WAF-1} Gene Activities" Molecular and Cellular Biology, Vol. 16, No. 4, pp. 1786-1793;
B13	Luo, Yan <i>et al.</i> (1995) "Cell-cycle Inhibition by Independent CDK and PCNA Binding domains In p21 ^{Cip1} " Nature Vol. 375, pp. 159-161;
B14	MacLachlan, Timothy K. (1995) "Cyclins, Cyclin-Dependent Kinases And Cdk Inhibitors: Implications In Cell Cycle Control And Cancer" Critical Reviews in Eukaryotic Gene Expression, Vol. 5, No. 2, pp. 127-156;

Examiner

Date Considered

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. CCI-007USDV	SERIAL NO. 10/646267
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Ball, Kathryn Lindsay et al.	
		FILING DATE August 22, 2003	GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

C1	Nakanishi, Makoto <i>et al.</i> (1995) "The C-Terminal Region Of p21 ^{SD11/WAF1/CIP1} Is Involved In Proliferating Cell Nuclear Antigen Binding But Does Not Appear To Be Required For Growth Inhibition" The Journal of biological Chemistry, Vol. 270, No. 29, pp. 17060-17063;
C2	Nakanishi, Makoto <i>et al.</i> (1995) "Identification Of The Active Region Of The DNA Synthesis Inhibitory Gene p21 ^{SD11/CIP1/WAF1} " The EMBO Journal, Vol. 14, No. 3, pp. 555-563;
C3	Flores-Rozas, Hernan <i>et al.</i> (1994) "Cdk-Interacting Protein 1 Directly Binds With Proliferating Cell Nuclear Antigen And Inhibits DNA Replication Catalyzed By The DNA Polymerase δ Holoenzyme" Proc. Natl. Acad. Sci. USA, Vol. 91, pp. 8655-8659;
C4	Su, Jin-Yuan <i>et al.</i> (1995) "Cloning And Characterization Of The Xenopus Cyclin-Dependent Kinase Inhibitor p27 ^{XIC1} " Proc. Natl. Acad. Sci. USA, Vol. 92, pp. 10187-10191;
C5	Voet <i>et al.</i> (1990) Biochemistry, John Wiley & Sons, Inc. pp 126-128, 228-234
C6	Waga, Shou <i>et al.</i> (1994) "The p21 Inhibitor Of Cyclin-Dependent Kinases Controls DNA Replication By Interaction With PCNA" Nature Vol. 369, pp. 574-578;
C7	Waldman, Todd <i>et al.</i> (1995) "p21 Is necessary For The p53-Mediated G ₁ Arrest In Human Cancer Cells" Cancer Research, Vol. 55, pp. 5187-5190;
C8	Warbrick, Emma <i>et al.</i> (1995) "A Small Peptide Inhibitor Of DNA Replication Defines The Site Of Interaction Between The Cyclin-Dependent Kinase Inhibitor p21 ^{WAF1} And proliferating Cell Nuclear Antigen" Current Biology, Vol. 5 No. 3, pp. 275-282;
C9	Warbrick, Emma <i>et al.</i> (1997) "Homologous Regions of Fen1 and p21 ^{Cip1} Compete For Binding To The Same Site On PCNA: A Potential Mechanism To Co-Ordinate DNA Replication And Repair" Oncogene, Vol. 14, pp. 2313-2321;
C10	Xiong, Yue <i>et al.</i> (1993) "p21 Is A Universal Inhibitor Of Cyclin Kinases" Nature Vol. 366, pp. 701-704;
C11	Zhang, Hui <i>et al.</i> (1994) "p21-Containing Cyclin Kinases Exist In Both Active And Inactive States" Genes & Development, Vol. 8, pp. 1750-1758.
Examiner	
Date Considered	

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.